Targets › CD8A
4 programs from 4 companies in 4 trials: 3 Phase 1, 1 Phase 2; Oncology, Neurology; next expected readout Jan 2027.
Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class I molecule:peptide complex. (UniProt, P01732)
Open in Phaseline: the race on CD8A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Medical Center Groningen | crefmirlimab anti-CD8 antibody for PET imaging | CD8A | Phase 2 | Locally Advanced Solid Tumor | Nov 2028 |
| Jonsson Comprehensive Cancer Center | Zirconium Zr 89 Crefmirlimab Berdoxam Radiolabeled anti-CD8+ minibody radioimmunoconjugate | CD8A | Phase 1 | Glioma | Jan 2027 |
| City of Hope Medical Center | Zirconium Zr 89-Df-Crefmirlimab Anti-CD8 positron emission tomography imaging agent | CD8A, CD8B | Phase 1 | Metastatic Malignant Solid Neoplasm | Oct 2027 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 89 Zr-Df-crefmirlimab Anti-CD8+ minibody conjugated with deferoxamine and radiolabeled with Zr-89 for PET imagin | CD8A | Phase 1 | Progressive Multifocal Leukoencephalopathy | Apr 2030 |
Locally Advanced Solid Tumor (1) Glioma (1) Metastatic Malignant Solid Neoplasm (1) Progressive Multifocal Leukoencephalopathy (1)
antibody (3)
University Medical Center Groningen (1) Jonsson Comprehensive Cancer Center (1) City of Hope Medical Center (1) National Institute of Neurological Disorders and Stroke (NINDS) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.